Document is current
Any future updates will be listed below
-
Authors
Serrano, Alejandra G.
Rocha, Pedro
Freitas Lima, Cibelle
Stewart, Allison https://orcid.org/0000-0002-7758-1179
Zhang, Bingnan
Diao, Lixia
Fujimoto, Junya
Cardnell, Robert J.
Lu, Wei
Khan, Khaja
Sable, Beate
Ellison, Aaron R.
Wistuba, Ignacio I.
Concannon, Kyle F.
Halperin, Daniel M.
Bogdan, Czerniak
Sircar, Kanishka
Zhang, Miao
Cargill, Kasey
Wang, Qi
Aparicio, Ana
Lazar, Alexander https://orcid.org/0000-0002-6395-4499
Hernandez, Sharia
Estrella, Jeannelyn
Ramalingam, Preetha
El-Naggar, Adel
Kalhor, Neda
Gay, Carl M.
Byers, Lauren Averett https://orcid.org/0000-0002-0780-2677
Solis Soto, Luisa M. https://orcid.org/0000-0002-1253-630X
- License Information
-
More Information
Article History
Received: 26 June 2024
Accepted: 18 October 2024
First Online: 19 November 2024
Competing interests
: D.M.H. reports to be consultant for Exelixis, Harpoon Therapeutics, ITM Novartis, Crinetics, Amryt, Camarus, Alphamedix, Chimeric Therapeutics, and research funded by Genentech, Thermofisher Scientific, ITM, AAA/Novartis, Camurus, RayzeBio. L.A.B. reports consulting or Advisory Board for Merck Sharp & Dohme Corp., Arrowhead Pharmaceuticals, Chugai Pharmaceutical Co., AstraZeneca Pharmaceuticals, Genetech Inc., BeiGene, AbbVie, Jazz Pharmaceuticals, Puma Biotechnology, Amgen Inc., Daiichi Sankyo, Novartis, and research funding from AstraZeneca Pharmaceuticals, Amgen Inc., Jazz Pharmaceuticals. A.R.E. reports to be a shareholder and former employee of Amgen Inc.
